Phase 1/2 program SBT101 for Adrenomyeloneuropathy (AMN) will be added to its clinical-stage pipeline
Spur Therapeutics have announced their acquisition of SwanBio Therapeutics, adding Phase 1/2 program for Adrenomyeloneuropathy (AMN) to its clinical-stage pipeline and strengthening CNS expertise. The AMN program, SBT101, is currently in a Phase 1/2 clinical trial, and Spur plans to report an initial safety update from the higher-dose cohort in this trial in the first half of next year. There are no approved treatments for AMN, and SBT101 is the only gene therapy candidate in development for the disease
We would like to assure our community that SwanBio have said that the study will continue despite the acquisition. The following comment was provided “The SwanBio team would like to take this moment to thank the AMN/ALD community for their support of the SBT101 program and express how much we, now as Spur Therapeutics, look forward to continuing the collaboration. The partnership of the patient and medical community has enabled the great progress achieved thus far in the Cygnet natural history study and the Propel Phase 1/2 study, and we truly appreciate the efforts of the community. As the program moves forward under the umbrella of Spur Therapeutics, we look forward to continuing to work with you towards the goal of delivering a transformative therapy for patients with AMN. We look forward to sharing updates on the SBT101 program’s progress later this year.”
To read the full press release: Spur Therapeutics Press Release
